Show simple item record

dc.contributor.authorColeman, David C
dc.contributor.authorMoran, Gary P
dc.contributor.authorMcManus, Brenda A
dc.contributor.authorSullivan, Derek J
dc.date.accessioned2011-03-10T12:58:49Z
dc.date.available2011-03-10T12:58:49Z
dc.date.issued2010-06
dc.identifier.citationMechanisms of antifungal drug resistance in Candida dubliniensis. 2010, 5 (6):935-49 Future Microbiolen
dc.identifier.issn1746-0921
dc.identifier.pmid20521937
dc.identifier.doi10.2217/fmb.10.51
dc.identifier.urihttp://hdl.handle.net/10147/124145
dc.description.abstractCandida dubliniensis was first described in 1995 and is the most closely related species to the predominant human fungal pathogen Candida albicans. C. dubliniensis is significantly less prevalent and less pathogenic than C. albicans and is primarily associated with infections in HIV-infected individuals and other immunocompromised cohorts. The population structure of C. dubliniensis consists of three well-defined major clades and is significantly less diverse than C. albicans. The majority of C. dubliniensis isolates are susceptible to antifungal drugs commonly used to treat Candida infections. To date only two major patterns of antifungal drug resistance have been identified and the molecular mechanisms of these are very similar to the resistance mechanisms that have been described previously in C. albicans. However, significant differences are evident in the predominant antifungal drug mechanisms employed by C. dubliniensis, differences that reflect its more clonal nature, its lower prevalence and characteristics of its genome, the complete sequence of which has only recently been determined.
dc.language.isoenen
dc.subject.meshAntifungal Agents
dc.subject.meshCandida
dc.subject.meshDrug Resistance, Fungal
dc.subject.meshHumans
dc.subject.meshModels, Biological
dc.titleMechanisms of antifungal drug resistance in Candida dubliniensis.en
dc.typeArticleen
dc.contributor.departmentMicrobiology Research Unit, Division of Oral Biosciences, Dublin Dental School & Hospital, University of Dublin, Trinity College Dublin, Dublin 2, Republic of Ireland. david.coleman@dental.tcd.ieen
dc.identifier.journalFuture microbiologyen
dc.description.provinceLeinster
html.description.abstractCandida dubliniensis was first described in 1995 and is the most closely related species to the predominant human fungal pathogen Candida albicans. C. dubliniensis is significantly less prevalent and less pathogenic than C. albicans and is primarily associated with infections in HIV-infected individuals and other immunocompromised cohorts. The population structure of C. dubliniensis consists of three well-defined major clades and is significantly less diverse than C. albicans. The majority of C. dubliniensis isolates are susceptible to antifungal drugs commonly used to treat Candida infections. To date only two major patterns of antifungal drug resistance have been identified and the molecular mechanisms of these are very similar to the resistance mechanisms that have been described previously in C. albicans. However, significant differences are evident in the predominant antifungal drug mechanisms employed by C. dubliniensis, differences that reflect its more clonal nature, its lower prevalence and characteristics of its genome, the complete sequence of which has only recently been determined.


This item appears in the following Collection(s)

Show simple item record